Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 6/20 | 0.55 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19200287 | 0.87 | SLC9A1 (0.54) | HCAR3SLC9A1MAPTPOLBNPC1 | |
| SCHEMBL24352983 | 0.81 | TDO2 (0.48) | HCAR3SLC9A1MAPTPOLB | |
| SCHEMBL3285240 | 0.77 | PKM (0.53) | HCAR3POLB | |
| SCHEMBL12376528 | 0.77 | KEAP1 (0.52) | HCAR3SLC9A1MAPTPOLBNPC1 | |
| SCHEMBL13523597 | 0.77 | HCAR3 (0.59) | HCAR3SLC9A1MAPTPOLBNPC1 | |
| SCHEMBL24296700 | 0.76 | PARP15 (0.39) | HCAR3MAPTNPC1RAB9A | |
| SCHEMBL23119707 | 0.76 | HCAR3 (0.58) | HCAR3SLC9A1MAPTPOLBNPC1 | |
| SCHEMBL18323591 | 0.76 | HCAR3 (0.58) | HCAR3SLC9A1MAPTPOLBNPC1 | |
| SCHEMBL24296719 | 0.76 | PARP15 (0.39) | HCAR3MAPTNPC1RAB9A | |
| SCHEMBL23222210 | 0.76 | MAPT (0.59) | HCAR3SLC9A1MAPTPOLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | SHY Therapeutics LLC | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | MAPK1, MAPK6, MAP3K1 | HCAR3 1149/4885SLC9A1 3778/4885MAPT 2188/4885 |
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | HCAR3 1255/4885SLC9A1 4129/4885MAPT 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.